AlgaeLife successful with NDI petition with FDA for astaxanthin ingredient

Image: AlgaeLife . Used with permission
Image: AlgaeLife . Used with permission

Related tags Dietary supplement

BGG subsidiary AlgaeLife Sciences, Inc. has successfully petitioned the US FDA with a New Dietary Ingredients notification (NDI) for its flagship product AstaZine Natural Astaxanthin. 

“Although we are not the first company to receive an NDI notification for Natural Astaxanthin, this NDI reinforces our commitment to provide the supplement industry with high quality ingredients that you can trust,” ​said Joe Huff, CEO of AlgaeLife’s US-based operation.   

“We are happy to have received a letter of acknowledgement without objection from FDA for our flagship product, AstaZine Natural Astaxanthin, which is derived from microalgae that we carefully cultivate in fully closed glass tube photobioreactors (PBRs) free from contamination.”

The ingredient is available in a variety of forms, said the company, including Organic Certified 5% powder; 5%, 10% and 20% oleoresin; 2% water soluble powder; 2.0% and 2.5% microencapsulated beadlets.  

Related news

Show more

Related products

show more

Related suppliers

Follow us


View more